1-Methyl-2-isobutylpyrrol | 71707-52-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: 1-Methyl-2-isobutylpyrrol
• 英文别名: 2-isobutyl-1-methyl-pyrrole；1-Methyl-2-(2-methylpropyl)pyrrole
• CAS: 71707-52-3
• 化学式: C₉H₁₅N
• 分子量: 137.225
• InChiKey: OILNDZAQRAEVQH-UHFFFAOYSA-N

物化性质

• 沸点：
  191.3±9.0 °C(Predicted)
• 密度：
  0.87±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  4.9
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为产物：
  描述：

  1-甲基吡咯-2-基锂 、 三(2-甲基丙基)硼烷 、 碘 以80%的产率得到
  参考文献：
  名称：

  SOTOYAMA T.; HARA S.; SUZUKI A., BULL. CHEM. SOC. JAP., 1979, 52, NO 6, 1865-1866

  摘要：

  DOI：

文献信息

• Methods and compositions of novel triazine compounds
  申请人：Timmer T. Richard

  公开号：US20070099874A1

  公开（公告）日：2007-05-03

  The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.

  本发明涉及用于治疗由炎症反应引起的病理生理状态的化合物的方法和组合物。特别地，本发明涉及抑制或阻断糖化蛋白诱导内皮细胞信号相关炎症反应的化合物。本发明涉及抑制平滑肌增殖的化合物。特别地，本发明涉及通过调节HSPG（如Perlecan）来抑制平滑肌细胞增殖的化合物。本发明进一步涉及使用化合物治疗由平滑肌增殖所特征的血管闭塞性疾病，例如再狭窄和动脉粥样硬化。
• NOVEL TYROSINE KINASE INHIBITORS
  申请人：Beaulieu Francis

  公开号：US20070135443A1

  公开（公告）日：2007-06-14

  The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase enzymes thereby making them useful as anti-cancer agents.

  本发明提供公式I化合物及其药学上可接受的盐。公式I化合物抑制酪氨酸激酶酶，因此可用作抗癌药物。
• NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO
  申请人：DYCK Brian

  公开号：US20110166116A1

  公开（公告）日：2011-07-07

  New compounds are disclosed which have utility in the treatment of a variety of metabolic related conditions in a patient. The compounds of this invention have the structure (I): wherein R 1 , R 2 , R 3 , n, p, q, and Ar are as defined herein, including stereoisomers, and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions comprising a compound of this invention, as well as methods relating to the use thereof in a patient in need thereof.

  本发明披露了一种新化合物，其在治疗患者的各种代谢相关疾病方面具有用途。本发明的化合物具有结构（I）：其中R1、R2、R3、n、p、q和Ar的定义如本文所述，包括立体异构体和药物可接受的盐。本发明还披露了包括本发明化合物的制药组合物，以及与在需要时使用该化合物的相关方法。
• MANDELAMIDE HETEROCYCLIC COMPOUNDS
  申请人：Cherney Robert J.

  公开号：US20130045964A1

  公开（公告）日：2013-02-21

  Disclosed are compounds of Formula (I) or stereoisomers, salts, or prodrugs thereof, wherein: Q is, or R 1 is phenyl substituted with zero to 3 substituents; and R 1 , R 2 , R 3 , R 4 , R 5 , and G are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

  本发明涉及式（I）的化合物或其立体异构体、盐或前药，其中：Q是，或R1是带有零到3个取代基的苯基；R1、R2、R3、R4、R5和G在此处被定义。还公开了使用这些化合物作为选择性G蛋白偶联受体S1P1的激动剂的方法，以及包含这些化合物的制药组合物。这些化合物在治疗、预防或减缓多种治疗领域的疾病或疾病的进展中有用，例如自身免疫性疾病和血管疾病。
• APPLICATION OF ?-QUATERNARY AMMONIUM BUTYRATE COMPOUND IN PREPARATION OF ANIMAL FEED ADDITIVE
  申请人：Peng, Xianfeng

  公开号：EP3935954A1

  公开（公告）日：2022-01-12

  Provided is an application of the γ-quaternary ammonium butyrate compound shown in structural formula (I) or a racemate, a stereoisomer, a tautomer, a solvate, or a feed-acceptable salt thereof in the preparation of an animal feed additive, the compound being added to the daily feed of animals at a certain concentration ratio, and being capable of increasing the average daily weight gain of animals under the same food intake conditions, having no significant effect on the daily feed intake of the animals, and reducing the feed-to-meat ratio. The γ-quatemary ammonium butyrate compound or a racemate, a stereoisomer, a tautomer, a solvate, or a feed-acceptable salt thereof can effectively increase the rate of daily weight gain of the animals and improve the growth performance of the animals, having no side effects on the animals, being stable and safe, and improving the production efficiency of the breeding industry whilst ensuring the health of the animals.

  本发明提供了一种结构式（I）所示的γ-季铵丁酸盐化合物或其外消旋体、立体异构体、同分异构体、溶解物或饲料可接受盐在制备动物饲料添加剂中的应用，该化合物以一定的浓度比添加到动物的日常饲料中，能够在相同的采食量条件下提高动物的平均日增重，对动物的日采食量无明显影响，并降低料肉比。丁酸γ-迷迭香铵化合物或其外消旋体、立体异构体、同分异构体、溶解物或饲料可接受盐能有效提高动物的日增重率，改善动物的生长性能，对动物无副作用，稳定安全，在保证动物健康的同时提高养殖业的生产效率。